The company faces mixed signals: an upcoming earnings report is not expected to beat estimates, and a mini-tender offer at a significant discount is being advised against. However, a new CEO has been given strong stock-based incentives, a dividend was increased for the 60th+ consecutive year, and analysts maintain a buy rating despite a lowered price target. Product innovation continues with a new Venus line, but growth targets are challenged by tariffs and a restructuring plan involving job cuts.